Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301, a Novel IL-18 Binding Protein, in Patients with Moderate-to-Severe Atopic Dermatitis

Evommune Inc. published this content on October 01, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 01, 2026 at 19:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]